Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
CLOZAPINE - CURRENT STATUS AND ROLE IN THE PHARMACOTHERAPY OF SCHIZOPHRENIA
Autore:
REMINGTON GJ; ADDINGTON D; COLLINS EJ; JONES BD; LALONDE P; MACCRIMMON DJ; MACEWAN GW;
Indirizzi:
CLARKE INST PSYCHIAT,CLIN INVEST UNIT,250 COLL ST TORONTO ON M5T 1R8 CANADA UNIV TORONTO,DEPT PSYCHIAT TORONTO ON CANADA UNIV CALGARY,DEPT PSYCHIAT CALGARY AB CANADA MCMASTER UNIV,DEPT PSYCHIAT HAMILTON ON CANADA UNIV MONTREAL,DEPT PSYCHIAT MONTREAL PQ H3C 3J7 CANADA UNIV BRITISH COLUMBIA,DEPT PSYCHIAT VANCOUVER BC CANADA
Titolo Testata:
Canadian journal of psychiatry
fascicolo: 3, volume: 41, anno: 1996,
pagine: 161 - 166
SICI:
0706-7437(1996)41:3<161:C-CSAR>2.0.ZU;2-V
Fonte:
ISI
Lingua:
ENG
Soggetto:
NEUROLEPTIC-RESISTANT SCHIZOPHRENIA; TREATMENT-REFRACTORY SCHIZOPHRENIA; TARDIVE-DYSKINESIA; ANTIPSYCHOTIC AGENT; COST-EFFECTIVENESS; EFFICACY; MULTICENTER; HALOPERIDOL; RISPERIDONE; DRUGS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Physical, Chemical & Earth Sciences
Science Citation Index Expanded
Citazioni:
71
Recensione:
Indirizzi per estratti:
Citazione:
G.J. Remington et al., "CLOZAPINE - CURRENT STATUS AND ROLE IN THE PHARMACOTHERAPY OF SCHIZOPHRENIA", Canadian journal of psychiatry, 41(3), 1996, pp. 161-166

Abstract

Objective: This study evaluates clozapine and its present role in thepharmacotherapy of schizophrenia. Method: Clozapine's current clinical status is reviewed, as is its position with respect to other treatment options. Results: Clozapine represents the prototype of ''atypical'' neuroleptics, with evidence of clinical efficacy in both positive and negative symptoms, as well as a diminished risk of extrapyramidal side effects. It is the only neuroleptic to date that has established itself as having little, if any, risk of tardive dyskinesia. More recentresearch has focused on its potential for overall savings in health care costs, as well as possible benefits in the area of neuropsychological functioning. Conclusion: Evidence suggesting that the course of schizophrenia can be altered by effective treatment favours a systematicapproach that optimizes treatment options. While clozapine does not represent a 1st-line agent because of its risk of agranulocytosis, it has an integral role to play in treatment-resistant schizophrenia or inindividuals experiencing intolerable side effects with conventional neuroleptics.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/12/20 alle ore 01:56:02